<DOC>
	<DOCNO>NCT00221468</DOCNO>
	<brief_summary>The purpose research study obtain preliminary data regard effectiveness , tolerability , safety quetiapine therapy adolescent mood disorder least one parent bipolar disorder ( severe mood swing ) .</brief_summary>
	<brief_title>A Study Quetiapine Treatment Mood Disorders Adolescents</brief_title>
	<detailed_description>Bipolar disorder common , life-long , progressive disease typically begin adolescence early adulthood associate significant morbidity mortality ( Lish et al. , 1994 ) . Family study show offspring parent bipolar disorder 30 % chance develop mood disorder , child parent mood disorder ( least one bipolar disorder ) 70 % chance develop mood disorder ( Goodwin Jamison 1990 ) . Indeed , child ( &lt; 18 year old ) even great risk develop bipolar disorder parent disorder ( review Lapalme et al. , 1997 ; DelBello Geller , 2002 ; Chang Steiner , 2003 ) . Since clinical manifestation bipolar disorder often present early life may worsen age , imperative illness recognize treat readily possible . Bipolar disorder may number prodromal early-onset presentation include syndromal mania . These prodrome may include cyclothymia , dysthymia , subsyndromal manic , depressive , mixed affective symptom ( Chang et al. , 2000 , review Lapalme et al. , 1997 ) . There several investigation divalproex treatment mood symptom child familial risk bipolar disorder ( Chang et al. , 2002 ; Findling et al. , 2002 ) . Chang et al. , find significant reduction mood symptom improvement overall functioning follow treatment divalproex 23 child bipolar I disorder diagnosed mood symptoms/syndromes parent bipolar disorder ( Chang et al. , 2002 ) . Similarly , Findling et al . report child mood symptom multigenerational family history bipolar disorder significant reduction mood symptom treat divalproex compare placebo ( Findling et al. , 2002 ) . To knowledge , study evaluate use atypical antipsychotic treatment child familial risk develop bipolar disorder diagnose mood disorder bipolar I disorder . Controlled investigation suggest quetiapine effective treatment mania adult adolescent ( Adityanjee Schulz , 2003 ; Sachs et al. , 2002 ; DelBello et al. , 2002 ) . Additionally , quetiapine particularly well-tolerated safe child adolescent ( DelBello et al. , 2002 ; Findling , 2003 ) . Our group report child risk bipolar disorder exhibit neurochemical abnormality , suggest neuronal damage may occur prior onset early course mood disorder . Furthermore , recent laboratory study suggest quetiapine may neuroprotective property ( Xu et al. , 2002 ) . Therefore , quetiapine ideal choice treatment adolescent familial risk develop bipolar disorder presently exhibit mood disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>To include study , subject must meet following criterion : 1 . Male female patient , 1218 year age . 2 . Female patient menarche must use medically accept mean contraception ( e.g . oral contraceptive , DepoProvera , abstinence ) . 3 . Each patient 's authorized legal guardian must understand nature study must provide write informed consent . Each patient must also give assent study participation . 4 . Patients must diagnosis Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) mood disorder ( dysthymia , major depressive disorder , depressive disorder otherwise specify , cyclothymic , bipolar I disorder , bipolar II disorder , bipolar disorder otherwise specify ) determine Washington University St. Louis Kiddie Schedule Affective Disorders Schizophrenia ( WASHU KSADS ) ( Geller et al. , 2000 ) . 5 . Patients must currently display symptom depression/dysthymia ( Childhood Depression Rating Scale &gt; 35 ) mania/hypomania ( Young Mania Rating Scale &gt; 14 ) . Patients exclude protocol follow reason : 1 . Female patient either pregnant lactating . 2 . Clinically significant unstable hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , immunologic , hematologic , systemic medical condition . 3 . Neurologic disorder include epilepsy , stroke , severe head trauma . 4 . Clinically significant laboratory abnormality follow test : complete blood count ( CBC ) differential , electrolytes , BUN , creatinine , hepatic transaminase , thyroid stimulate hormone ( TSH ) , electrocardiogram ( EKG ) . 5 . Mood symptom due general medical condition substanceinduced mania ( DSMIV ) . 6 . Mental retardation ( intelligence quotient [ IQ ] &lt; 70 ) . 7 . History hypersensitivity intolerance quetiapine . 8 . Prior history quetiapine nonresponse . 9 . DSMIV substance ( except nicotine caffeine ) dependence within past 3 month . 10 . Judged clinically serious suicidal risk . 11 . Participation clinical trial another investigational drug within 1 month ( 30 day ) prior study entry . 12 . Treatment injectable depot neuroleptic within less one dosing interval depot neuroleptic injection day 0 . 13 . Treatment concurrent mood stabilizer anticonvulsant , benzodiazepine ( except describe ) , psychostimulants , guanethidine , guanadrel , antidepressant . 14 . Schizophrenia psychotic disorder ( include schizophreniform disorder , schizoaffective disorder , delusional disorder , brief psychotic disorder , share psychotic disorder , psychotic disorder due general medical condition , substanceinduced psychotic disorder , psychotic disorder otherwise specify ) define DSMIV .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Adolescents</keyword>
</DOC>